Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian F Pollack

Showing results (31-40 of 308) with videos related to

Pageof 31
Sort By:
Cancer Letters|September 29, 2007
AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylationEsther P Jane, Daniel R Premkumar, Ian F Pollack
Molecular Cancer Therapeutics|January 12, 2011
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathwayEsther P Jane, Daniel R Premkumar, Ian F Pollack
Cancer Biology & Therapy|December 9, 2014
Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsDaniel R Premkumar, Esther P Jane, Ian F Pollack
Brain Pathology (Zurich, Switzerland)|May 5, 2010
A 10-year old girl with neck painCraig Horbinski, Ian F Pollack, Clayton Wiley, et al.
Seminars in Radiation Oncology|December 5, 2009
Brain tumors across the age spectrum: biology, therapy, and late effectsThomas E Merchant, Ian F Pollack, Jay S Loeffler
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cellsEsther P Jane, Daniel R Premkumar, Ian F Pollack
Acta Neuropathologica|January 2, 2010
Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomasCraig Horbinski, Ronald L Hamilton, Yuri Nikiforov, et al.
Current Oncology Reports|February 2, 2002
Risk assignment in childhood brain tumors: the emerging role of molecular and biologic classificationIan F Pollack, Jaclyn Biegel, Allan Yates, et al.
Neurosurgery|July 11, 2013
Peptide vaccine therapy for childhood gliomasIan F Pollack, Regina I Jakacki, Lisa H Butterfield, et al.
Expert Review of Neurotherapeutics|October 15, 2013
Ependymomas: development of immunotherapeutic strategiesIan F Pollack, Regina I Jakacki, Lisa H Butterfield, et al.
Pageof 31

Showing results (31-40 of 308) with videos related to

Sort By:
Pageof 31
Cancer Letters|September 29, 2007
AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylationEsther P Jane, Daniel R Premkumar, Ian F Pollack
Molecular Cancer Therapeutics|January 12, 2011
Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathwayEsther P Jane, Daniel R Premkumar, Ian F Pollack
Cancer Biology & Therapy|December 9, 2014
Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsDaniel R Premkumar, Esther P Jane, Ian F Pollack
Brain Pathology (Zurich, Switzerland)|May 5, 2010
A 10-year old girl with neck painCraig Horbinski, Ian F Pollack, Clayton Wiley, et al.
Seminars in Radiation Oncology|December 5, 2009
Brain tumors across the age spectrum: biology, therapy, and late effectsThomas E Merchant, Ian F Pollack, Jay S Loeffler
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cellsEsther P Jane, Daniel R Premkumar, Ian F Pollack
Acta Neuropathologica|January 2, 2010
Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomasCraig Horbinski, Ronald L Hamilton, Yuri Nikiforov, et al.
Current Oncology Reports|February 2, 2002
Risk assignment in childhood brain tumors: the emerging role of molecular and biologic classificationIan F Pollack, Jaclyn Biegel, Allan Yates, et al.
Neurosurgery|July 11, 2013
Peptide vaccine therapy for childhood gliomasIan F Pollack, Regina I Jakacki, Lisa H Butterfield, et al.
Expert Review of Neurotherapeutics|October 15, 2013
Ependymomas: development of immunotherapeutic strategiesIan F Pollack, Regina I Jakacki, Lisa H Butterfield, et al.
Pageof 31